1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
AnGes. Inc.

AnGes. Inc.

0.17
EUR
0.00
(0.00%)
101.30MMarket Cap
Nov 06Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
16.35
23.86
7.74
8.11
4.79
7.02
3.12
0.34
0.44
0.43
0.81
2.74
2.46
- -
Basic EPS, GAAP
-46.91
-62.12
-74.53
-75.29
-49.38
-34.46
-35.81
-35.33
-92.86
-94.29
-39.29
-119.53
-14.44
- -
Free Cash Flow per Basic Share
-48.96
-71.37
-83.87
-79.67
-39.36
-29.59
-20.88
-25.53
-77.82
-71.99
-46.68
-28.43
-16.25
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
96.08
144.45
74.66
54.78
45.43
78.94
112.7
245.6
252.4
170.33
131.52
7.53
7.91
0.52
Tangible Book Value per Share
94.19
143.44
73.75
54
45.43
78.94
112.7
74.9
104.26
40.15
21.95
7.5
7.89
0.5
Basic Weighted Avg Shares
30
38
56
63
76
87
105
119
147
156
189
235
355
379
Sales/Revenue/Turnover
491
910
430
514
365
610
327
40
64
67
153
644
874
- -
Operating Margin (%)
-277.45
-249.9
-969.88
-926.24
-900.56
-502.46
-1,000.74
-13,999.18
-24,369.16
-24,331.65
-7,822.66
-1,415.31
-588.64
- -
Depreciation Expense
60
46
49
67
29
8
7
8
2,426
2,902
3,109
3,372
54
- -
Net Income, GAAP
-1,410
-2,369
-4,143
-4,777
-3,765
-2,997
-3,751
-4,210
-13,676
-14,715
-7,438
-28,129
-5,123
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-286.92
-260.37
-963.22
-928.85
-1,030.91
-491.21
-1,147.89
-10,524.3
-21,319.14
-21,942.7
-4,861.66
-4,370.31
-586.11
- -
Working Capital
2,959
7,171
3,761
2,989
3,116
7,251
10,549
8,577
14,693
5,573
3,428
1,229
2,143
-132
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
995
215
109
- -
615
Total Equity
3,544
7,734
4,221
3,869
3,622
7,734
12,055
32,680
38,635
30,425
26,103
2,157
3,076
206
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-53.38
-42.01
-69.31
-118.08
-100.51
-52.77
-37.91
-18.82
-38.35
-42.61
-26.31
-199.07
-195.82
- -

Capital Structure

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
ST Debt
162
- -
109
LT Borrowings
- -
- -
592
LT Finance Leases
174
- -
23
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
237
396
399
Market Capitalization
10,965
22,391
18,815

Working Capital

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
Total Current Assets
3,591
- -
2,620
Cash, Cash Equivalents & STI
1,821
- -
282
Accounts Receivable, Net
200
- -
99
Inventories
1,303
- -
1,713
Total Current Liabilities
1,929
- -
2,752
Payables & Accruals
- -
- -
- -
ST Debt
162
- -
109
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.94%
-13.27%
42.64%
Free Cash Flow
19.29%
43.05%
-13.84%
Net Income, GAAP
39.05%
75.89%
-81.79%
Sales/Revenue/Turnover
47.3%
109.92%
35.81%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
114
234
- -
- -
644
2025
- -
- -
- -
- -
874
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-9.14
-7.46
- -
- -
-119.53
2025
- -
- -
- -
- -
-14.44
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ei Yamada
Full Time Employees
56
Sector
Health technology
Industry
Pharmaceuticals: generic
Address
Saito Bio-Incubator Osaka OS Japan 567-0085
IPO Date
Sep 25, 2002
Website
anges.co.jp
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Jagsonpal Pharmaceuticals Ltd. (NSE:JAGSNPHARM)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Business
AnGes, Inc. (4563.T) develops and commercializes gene medicines and nucleic acid therapeutics for unmet medical needs, primarily focusing on cardiovascular, neurological, and rare diseases. The company offers core products and services including its proprietary Hydrodynamic Gene Delivery technology for non-viral gene transfer; gene therapy candidates such as Collategene (VFGF/HGF plasmid DNA) approved for critical limb ischemia in Japan; preclinical and clinical-stage pipeline assets targeting conditions like hypertrophic cardiomyopathy, moyamoya disease, and diabetic foot ulcers; and nucleic acid medicine platforms like circular RNA and miRNA therapeutics. Operations span research, development, manufacturing, and commercialization primarily in Japan, with clinical trials and partnerships extending to Asia, Europe, and the United States; founded in 1999, AnGes is headquartered in Ibaraki, Osaka, Japan. In recent developments, the company advanced its pipeline with Phase I/II trial initiations for AG2X-314 in hypertrophic cardiomyopathy and reported positive preclinical data for circular RNA-based therapeutics in 2024; it formed strategic alliances with VBL Therapeutics for cancer gene therapy combinations and entered a collaboration with Kyoto University for miRNA research targeting neurological disorders; additionally, AnGes secured funding through a JPY 1.2 billion rights offering in early 2025 and expanded manufacturing capabilities at its Osaka facility to support global clinical supply.